Peptide Therapy
AOD-9604
Advanced Fat Metabolism Support
A modified peptide fragment designed to support your body's natural fat metabolism—without affecting growth hormone levels, insulin sensitivity, or appetite.
Rx
Consultation Required
SC
Subcutaneous Injection
2000
First Metabolic Studies Published
22+
BHRC Locations
The Science
What is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from human growth hormone—specifically amino acids 176-191. It was engineered to isolate the fat-metabolizing properties of HGH without triggering its growth-promoting effects.
The peptide works by stimulating lipolysis (fat breakdown) while inhibiting lipogenesis (new fat formation). Unlike complete growth hormone therapy, AOD-9604 does not elevate IGF-1 levels or affect blood sugar regulation.
At BHRC, our providers customize AOD-9604 protocols as part of comprehensive wellness programs that include nutrition guidance and lifestyle optimization for sustainable results.
Book a Consultation
HGH fragment (aa 176-191)
Targets fat tissue selectively
No IGF-1 or insulin impact
No appetite changes
Subcutaneous injection
Potential Benefits
Why Consider AOD-9604?
Targeted Fat Metabolism
Works specifically on adipose tissue, supporting the breakdown of stored fat while inhibiting new fat cell formation.
Metabolic Support
Mimics how natural growth hormone regulates fat metabolism, potentially supporting overall metabolic function.
Selective Action
Does not significantly affect IGF-1 levels, blood sugar, or promote tissue growth—more targeted than full HGH.
No Appetite Changes
Does not increase hunger or elevate cortisol, allowing you to maintain your nutrition plan without interference.
Joint Support Potential
Emerging research suggests possible benefits for cartilage health, though more studies are needed to confirm.
Well-Tolerated
Human safety data are limited; FDA notes it lacks sufficient safety information, so tolerability is reviewed at every follow-up.
Your Journey
How It Works at BHRC
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Consultation
Discuss your goals, review health history, and determine if AOD-9604 is appropriate.
Custom Protocol
Receive a personalized treatment plan with precise dosing and lifestyle recommendations.
Training
Learn proper subcutaneous injection technique from our clinical staff.
Ongoing Care
Regular follow-ups to monitor progress and optimize your protocol over time.
Safety Profile
A Well-Studied Compound
AOD-9604 is studied as a fragment that differs from full growth hormone therapy; published human safety data remain limited.
- No IGF-1 elevation — avoids systemic growth effects
- No blood sugar impact — maintains glucose homeostasis
- No tissue overgrowth — selective fat metabolism action
- Provider supervised — screening and follow-up at every stage
Not FDA
Approved for any use; prescribed only after consultation
Rx
Provider consultation and documented consent required
Free virtual consult
Talk to Stephanie Starin, NP, from home
A free 60-minute video visit. Ask about peptide therapy or medical weight loss, get your questions answered, and leave with a plan from a licensed provider.
At a glance
AOD-9604 at BHRC: the essentials
- What it is
- A modified fragment of the tail end of human growth hormone, studied from around 2000 as an anti-obesity candidate. It is not growth hormone and is not intended to raise IGF-1.
- What it is used for
- As an adjunct in supervised body-composition plans, for people already committed to nutrition and training. It is not an appetite suppressant.
- How it's given
- A small injection under the skin after in-clinic training; details are covered in our dosage guide and at consultation.
- Honest expectation
- Modest at best. Animal studies showed increased fat breakdown, but peer-reviewed human efficacy trials are not available in PubMed, and there is no published evidence that it matches approved weight-loss medications.
- Who it suits
- Adults near their goal who want supervised support for stubborn fat, or who cannot or prefer not to use a GLP-1.
- Regulatory status
- Not FDA-approved. Previously in FDA's compounding Category 2; the nomination was withdrawn, and it is not on the 503A bulks list.
Your plan
What a AOD-9604 plan at BHRC involves
1
A body-composition consultation
The BHRC clinical team starts with your goal, weight history, what you have already tried and why. Someone with significant weight to lose is usually better served by an approved medication, and the team will say so plainly.
2
Baseline measurements
Body composition, waist measurement, blood pressure, fasting glucose, HbA1c and lipids. These are the numbers that show whether anything changed, rather than the bathroom scale alone.
3
Choosing the right tool
AOD-9604 is compared with approved options such as semaglutide or tirzepatide, and with non-drug changes. If you qualify for an approved medication and want the larger effect, that is usually the recommendation; AOD-9604 is chosen when the goal is modest or a GLP-1 is not right for you.
4
Prescription and training
If prescribed, it comes from a licensed pharmacy with injection training and written instructions. Your schedule is set by the clinical team and explained in our dosage guide.
5
Measured follow-up
Body composition and labs are repeated at set intervals, and nutrition and training are reviewed at the same visit. If the numbers have not moved after a fair trial, the plan changes, either to a different tool or to stopping, and you are told plainly which and why.
Timeline
What to expect with AOD-9604, step by step
- Consultation
Goals, history, baseline body composition and labs. A recommendation on whether AOD-9604 or an approved medication fits better.
- First month
Most people notice little on the scale. Appetite does not usually change, which is expected for this peptide, so the nutrition plan does the heavy lifting in these weeks.
- Around 6 to 8 weeks
First body-composition recheck. Small changes in waist or fat mass, if any, start to show here.
- Around 3 months
The main decision point: continue, adjust the wider plan, or move to a different option.
- After stopping
Results depend on the habits that carried the plan. Without them, any change tends not to last, which is why the final visit focuses on a maintenance plan rather than on the peptide.
Compare
AOD-9604 compared with other options
| Option | How it works | FDA status | Typical fit |
|---|---|---|---|
| AOD-9604 (this page) | GH fragment studied for fat breakdown | Not approved; previously Category 2 | Modest, supervised adjunct; no appetite effect |
| Semaglutide | GLP-1 receptor agonist, reduces appetite | Approved (Wegovy) for chronic weight management | Larger weight loss for eligible adults; see our semaglutide page |
| Tirzepatide | GIP and GLP-1 agonist | Approved (Zepbound) for chronic weight management | Larger weight loss for eligible adults; see our tirzepatide page |
| 5-Amino-1MQ | Oral NNMT inhibitor, metabolic research | Not approved | Alternative adjunct discussed for some patients; see that page |
Is it right for you?
Who AOD-9604 may suit, and who should not use it
May be a fit if
- Adults close to their goal weight who want supervised support for body composition
- People already consistent with nutrition and training who want to try a modest adjunct
- Patients who cannot use, or do not want, a GLP-1 medication
- Those willing to judge it on body-composition data over a defined period
Not a fit if
- Anyone with significant weight to lose who qualifies for an approved medication and wants a larger effect
- Active cancer or a cancer history
- Pregnancy, trying to conceive or breastfeeding
- Uncontrolled diabetes or unexplained weight loss, which need medical evaluation
- Competitive athletes subject to drug testing, since anti-doping labs test for it
- People hoping it will reduce appetite; it is not designed to
- Anyone looking for a quick result before an event; it is a slow, modest adjunct at best
Monitoring
How BHRC monitors AOD-9604
AOD-9604 is judged on body composition, not on feel. Fat mass, lean mass and waist measurement at baseline and at follow-up tell the BHRC clinical team whether the peptide is adding anything to your nutrition and training. If those numbers have not moved after a fair trial, continuing is not good value, and the team will say so.
Safety monitoring is straightforward but taken seriously. FDA's summary notes it lacks sufficient safety information for the proposed routes and has identified serious adverse events that may be associated with AOD-9604, although causality is not clear. Injection-site reactions, headaches and any unusual symptom are recorded, and fasting glucose and lipids are repeated at follow-up.
On evidence, the picture is thinner than marketing suggests. The published research in PubMed is mainly animal and laboratory work: studies in obese mice showing more fat oxidation and weight loss, and metabolic studies of the lipolytic fragment. Claims of large human trial programmes and food-safety designations circulate widely, but we could not verify peer-reviewed human efficacy results in PubMed, so they are not used on this page.
What counts as a fair trial? The team agrees the measurement method at the start, usually a body-composition scan plus waist measurement, and repeats it under the same conditions: same time of day, similar hydration, no hard training session just before. Changes of a pound or two on a scale are noise; a consistent drop in fat mass with lean mass held steady is the signal. If that signal is absent at the main review point, the plan changes rather than the course being extended in hope.
Because AOD-9604 does not reduce appetite, the nutrition side of the plan carries more weight than it would with a GLP-1 medication. Patients who choose it are usually given a protein target, a realistic calorie range and a training plan that protects muscle, and the follow-up visits review those as closely as the injections. People whose main struggle is hunger or cravings are usually better matched to a different tool, and the team will steer the conversation that way.
Some patients come to AOD-9604 because a GLP-1 is not an option for them, for example a family history of medullary thyroid cancer, a history of pancreatitis, or gastrointestinal side effects they could not tolerate. In those cases the team is clear about the trade: a gentler, appetite-neutral adjunct with a much smaller expected effect and thinner evidence, in exchange for avoiding a medication that does not suit them. Other options, including non-drug approaches and other approved medications, are discussed at the same visit.
Anti-doping laboratories have published methods to detect AOD-9604 and its metabolites, so tested athletes should not use it.
Dosing, reconstitution and cycling detail is covered in our AOD-9604 dosage guide. Your own plan is set by your provider at the consultation.
Regulatory status
AOD-9604: FDA status and how it is prescribed
AOD-9604 is not FDA-approved for weight loss or any other use, and no FDA-approved product contains it. FDA previously placed AOD-9604 in Category 2 of its 503A interim policy (substances that may present significant safety risks), noting immunogenicity concerns, limited safety information and serious adverse events that may be associated with it, though causality is not clear; the nomination was withdrawn by the nominator, and AOD-9604 is not on the 503A bulks list. At BHRC it is prescribed only after a provider consultation, with baseline measurements and documented informed consent. Prepared by the BHRC team from FDA and PubMed sources.
Before you book
AOD-9604: cost, consultation and safety questions
What is AOD-9604 used for?
It is used as a supervised adjunct in body-composition plans, mainly by people who are already eating and training well and want support with stubborn fat. It is not approved for weight loss or any other condition, and it does not reduce appetite.
Is AOD-9604 a growth hormone?
No. It is a small modified fragment from the end of the growth hormone molecule. It was designed to keep the fat-metabolism activity seen in that region without the growth effects of full growth hormone, and it is not intended to raise IGF-1. That makes it a different category from growth-hormone secretagogues such as sermorelin or ipamorelin, which ask the pituitary to release more of your own growth hormone; if your goals are sleep and recovery rather than fat loss, those pages are the more relevant ones.
What does an AOD shot do?
In animal studies, AOD-9604 increased fat breakdown and reduced fat gain. In people, the effect is expected to be modest and depends heavily on diet and activity. The BHRC team measures it with body-composition testing rather than promising a number.
What are the benefits of AOD-9604?
The reported benefits come mostly from animal research on fat metabolism. For a patient, the realistic benefit is a possible small improvement in body composition alongside a good plan, without the appetite changes of GLP-1 medications. It is not a substitute for those medications when a larger effect is needed.
How should AOD-9604 be dosed?
Dosing, timing and administration are covered in detail in our AOD-9604 dosage guide. Your own schedule is set by the clinical team at consultation.
AOD-9604 vs semaglutide: which is better for weight loss?
For meaningful weight loss in eligible adults, approved GLP-1 medications such as semaglutide have far stronger evidence from large trials. AOD-9604 is a different tool: smaller expected effect, no appetite change, and for people who cannot or do not want to use a GLP-1. Some patients finish a GLP-1 course and ask about AOD-9604 for maintenance; the team reviews that case by case, since the habits built during the GLP-1 course usually matter more than any adjunct.
Is AOD-9604 safe?
Its human safety profile is not well established in published research, and FDA has noted possible serious adverse events with unclear causality. Injection-site redness is the effect most often reported in supervised plans, but with so little published human data the team does not call it proven safe.
Is AOD-9604 FDA approved?
No. It is not approved for any use, it was previously placed in Category 2 of FDA's compounding policy, and it is not on the 503A bulks list. BHRC prescribes it only after a consultation and explains the status in writing.
What does AOD-9604 cost?
Cost depends on the consultation, baseline body-composition testing and labs, how many vials your plan needs, and the number of follow-up visits. If an approved medication is a better fit, the team will quote that instead. Your BHRC centre provides an itemised quote; prices are not on this page.
How do I start?
Book a body-composition consultation. Bring your weight history and any recent labs, and tell the team what you have tried before, including any medications that did not suit you. The recommendation may be AOD-9604, an approved medication or a plan without either, and you leave the first visit knowing which and why.
Selected research
Published research on AOD-9604
The literature below is peer-reviewed background on AOD-9604 and the mechanisms discussed on this page, so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and some of it is preclinical work in animals or cells. Your provider will discuss what the evidence does and does not support for your situation.
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res (2000). PubMed 11146367
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology (2001). PubMed 11713213
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord (2001). PubMed 11673763
- AOD-9604 Metabolic. Curr Opin Investig Drugs (2004). PubMed 15134286
- Detection and in vitro metabolism of AOD9604. Drug Test Anal (2015). PubMed 25208511
- Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med (2026). PubMed 41966639
Related peptide therapies
Often considered alongside AOD-9604
Questions
Frequently Asked
How is AOD-9604 administered?
AOD-9604 is administered via subcutaneous injection into the fatty layer beneath the skin. Our clinical team provides thorough training on proper technique, storage, and handling during your initial visit.
What results can I expect?
Results vary based on individual factors including diet, exercise, and metabolic baseline. AOD-9604 works best as part of a comprehensive wellness approach. Most protocols recommend consistent use over several weeks to months.
Is AOD-9604 the same as HGH?
No. AOD-9604 is a small fragment (amino acids 176-191) of human growth hormone, specifically modified to target fat metabolism. Unlike full HGH, it does not affect IGF-1, insulin sensitivity, or promote tissue growth.
Who is a good candidate?
AOD-9604 may be appropriate for adults seeking additional support for body composition goals who are already committed to healthy nutrition and exercise. A physician consultation will determine if it's right for you.
Are there any side effects?
Mild injection-site reactions are the effect most often reported, though human data are limited. Some individuals may experience mild injection site reactions. Our medical team reviews your complete health history to ensure this therapy is appropriate.
Get Started
Begin Your Transformation
Schedule a consultation with our medical team to learn if AOD-9604 peptide therapy is right for your wellness journey.
"*" indicates required fields
Free virtual consult
Talk to Stephanie Starin, NP, from home
A free 60-minute video visit. Ask about peptide therapy or medical weight loss, get your questions answered, and leave with a plan from a licensed provider.
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. AOD-9604 is administered under medical supervision as part of a comprehensive wellness program. Individual results may vary. A consultation with our medical team is required to determine if this therapy is appropriate for you.